



PRESS RELEASE

Half year report on Adocia's liquidity agreement with Kepler Chevreux

Lyon, France, January 6th, 2017 – Under the liquidity agreement entrusted by Adocia to Kepler Chevreux, the following resources were listed on the liquidity account as at December 30, 2016:

- 760 shares of Adocia and
- 335,365.88 euros in cash.

At the last half year report dated June 30, 2016:

- 3,575 shares of Adocia and
- 149,679.76 euros in cash.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com



ENTERNEXT | TECH40 | LABEL | 2015



ADOC
LISTED
EURONEXT

For more information please contact:

| | | |
|---|--|---|
| <p>Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Tél. : +33 4 72 610 610</p> | <p>Adocia Press Relations Europe MC Services AG Raimund Gabriel raimund.gabriel@mc-services.eu adocia@mc-services.eu Tél. : +49 89 210 228 0</p> | <p>Adocia Investor Relations USA The Ruth Group Tram Bui tbui@theruthgroup.com Tel. : +1 646 536 7035</p> |
|---|--|---|